Clinical Evidence

Delve into clinical research studies and more

Clinical research lies at the heart of who we are. Vantive uses scientific evidence systematically, and transparently, to inform the development of new state-of-the-art solutions for patients around the world. Here you can find various studies, white papers and articles concerning important topics across the wide range of therapy areas served by Vantive.

HDx therapy enabled by the Theranova Dialyzer
New medium cut-off membrane vs online hemodiafiltration in clearance of middle molecules. Preliminary results from our centre
Visit resource site
PD
Novel applications of remote patient management to improve outcomes in peritoneal dialysis
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
On the balance between albumin loss and removal of middle molecules in dialyzers
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
On the balance between albumin loss and removal of middle molecules in dialyzers
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
On the Removal of Middle Molecules and Albumin Loss: An Ex Vivo Evaluation of Commercial Dialyzers
Visit resource site
PD
Patient Expectations and Experiences of remote monitoring for chronic diseases: Systematic review and thematic synthesis of qualitative studies – Walker R, et. al.
Visit resource site
PD
PD Cycler With 2-Way Remote Management Technology Reveals Patient Adherence Patterns to Dialysis - Firanek CA, et al.
Download PDF
HDx therapy enabled by the Theranova Dialyzer
Performance of hemodialysis with novel medium cut-off dialyzers - Kirsch AH, et al.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Performance of medium cut-off dialyzers in expanded hemodialysis patients in Colombia
Visit resource site
PD
Perspectives from the Kidney Health Initiative on Advancing Technologies to Facilitate Remote Monitoring of Patient Self-Care in RRT - Rosner et al.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Preliminary data from mother HDx study: a multicentre open-label RCT study to explore the morbimortality with the Theranova HDx vs OL-HDF
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Prevalence of fatigue reported by patients on hemodialysis therapy
Visit resource site

Important Safety Information

INTENDED USE

The Theranova Dialyzer is indicated for patients with chronic kidney failure who are prescribed intermittent hemodialysis. It provides an expanded solute removal profile with increased removal of various middle molecules (up to 45 kDa) that may play a pathologic role in the uremic clinical syndrome. The Theranova Dialyzer is not intended for hemofiltration or hemodiafiltration therapy. The total extracorporeal blood volume for the Theranova Dialyzer and the set should represent less than 10% of the patient's blood volume.

For single use only.

 

Rx Only. For safe and proper use of the products mentioned herein, please refer to the appropriate Operator’s Manual or Instructions for Use.

 

Vantive, HDx and Theranova are trademarks of Vantive Health LLC or its affiliates.